CD20-directed Cytolytic Antibody [EPC]

178653 reported adverse events

Drugs of this class: OFATUMUMAB OBINUTUZUMAB OCRELIZUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 23250
1 OFF LABEL USE 17324
2 FATIGUE 13632
3 RHEUMATOID ARTHRITIS 12683
4 PAIN 11791
5 PYREXIA 8201
6 INFUSION RELATED REACTION 8013
7 NAUSEA 7968
8 RASH 7901
9 ARTHRALGIA 7798
See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 2072 0.8022
1 SWOLLEN JOINT COUNT INCREASED 394 0.7710
2 RED BLOOD CELL SEDIMENTATION RATE 150 0.7538
3 CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT 308 0.6860
4 SARS-COV-2 ANTIBODY TEST NEGATIVE 141 0.6589
5 PEMPHIGUS 4346 0.6490
6 B-CELL LYMPHOMA RECURRENT 263 0.6415
7 RHEUMATOID FACTOR POSITIVE 1607 0.6255
8 MANTLE CELL LYMPHOMA RECURRENT 131 0.6037
9 GRANULOMA SKIN 358 0.6017
See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]